ATXI AVENUE THERAPEUTICS, INC.
Pharmaceutical Preparations · OTC · SEC CIK 1644963 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY25.6%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-160.0%
ROA-106.0%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets104.9%
Debt / equity—
Current ratio—
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.79x
Accruals ratio-22.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY2023*2023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.40M | $0 | — | — | — |
| R&D expense | $1.04M | $6.64M | $6.13M | $2.70M | $1.25M |
| SG&A expense | $3.65M | $4.64M | $4.18M | $5.34M | $2.48M |
| Operating income | -$3.08M | -$11.28M | -$14.54M | -$8.04M | -$3.74M |
| Income tax | $2,000 | $0 | $0 | $0 | — |
| Net income | -$2.91M | -$11.65M | -$10.38M | -$3.55M | -$3.73M |
| EPS (basic) | -0.93 | -15.79 | -73.48 | -1.63 | -0.22 |
| EPS (diluted) | — | — | — | — | -0.22 |
| Weighted avg. shares (diluted) | — | — | — | 2.19M | 1.13M |
| Balance sheet | |||||
| Cash & equivalents | $2.85M | $2.59M | $1.78M | $6.71M | $3.76M |
| Current assets | — | — | — | — | $3.96M |
| Total assets | $2.93M | $2.67M | $1.85M | $6.84M | $3.96M |
| Current liabilities | $1.10M | $816,000 | $1.20M | $3.58M | $509,000 |
| Total liabilities | $1.10M | $816,000 | $1.20M | $3.58M | $509,000 |
| Shareholders' equity | $1.83M | $2.80M | $1.58M | $3.90M | $3.45M |
| Shares outstanding | 3.18M | 2.11M | 341,324 | 4.77M | 1.41M |
| Cash flow statement | |||||
| Operating cash flow | -$1.83M | -$9.03M | -$9.45M | -$7.60M | -$3.75M |
| Investing cash flow | — | $0 | -$3.00M | $0 | — |
| Financing cash flow | $2.09M | $9.84M | $7.53M | $10.54M | $4.38M |
| Stock-based compensation | $665,000 | $1.24M | $906,000 | $649,000 | $442,000 |
| Share buybacks | — | — | $0 | $1.10M | — |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.